Press Brief

5:00
A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL
Laurie Sehn
3:47
Sickle cell disease: where we are now
Maria Cappellini
5:57
Making CAR T-cells happen in Europe
John Gribben
6:23
Exciting new therapy for Waldenström’s macroglobulinemia: ibrutinib plus rituximab
Meletios Dimopoulos
4:23
New CD22 CAR T-cells for pediatric R/R B-ALL are highly effective
Jing Pan
5:44
Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL
Valentin Goede
4:15
Advanced Hodgkin lymphoma: AHL2011 data update from EHA 2018
Olivier Casasnovas
6:07
Big data for HemOnc in Europe: HARMONY
Jesús María Hernández Rivas
6:39
Update on bb2121 CAR T-cell product for MM from EHA 2018
Jesús Berdeja
6:38
Follicular lymphoma: is RELEVANCE relevant?
Frank Morschhauser
5:48
Iron and inflammation in anemia and sickle cell disease
Francesca Vinchi
7:11
First-in-human CLL1-CD33 compound CAR T-cells for AML
Fang Liu
3:58
ZUMA-1: a pivotal trial of CAR T-cells in NHL
Yi Lin
4:35
The use of anticoagulants in cancer-associated venous thromboembolism
Alejandro Lazo-Langner
6:30
GHSD HD18 study: reducing chemotherapy toxicity in advanced stage Hodgkin lymphoma
Peter Borchmann
4:38
Different is better: the fight against leukemia
Michaela Kotrová
The content of VJHemOnc is intended for healthcare professionals